Furthermore, recent preclinical and clinical data indicate that avelumab, a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential Ab-mediated CDC, can be safely administered to cancer patients with a toxicity profile comparable to other mAbs and without lysis of PD-L1-positive activated immune cells. This evidence concerns the gene CD274 and cancer.